Mark Foletta Insider Profile

4 Followers
Mark Foletta, Interim CFO at Biocept, holds 0.00 shares in Biocept (Ticker: BIOCQ), holds 15.04K shares in Forte Biosciences (Ticker: FBRX), holds ― shares in Enanta Pharmaceuticals (Ticker: ENTA). Most recently, Mark Foletta ― shares of Biocept on ― for an estimated value of ―.
tipranks
Mark Foletta

Mark Foletta
Biocept (BIOCQ)
Interim CFO

Ranked #93,369 out of 99,335 Corporate Insiders

Profitable Transactions

11%
1 out of 9 Profitable Transactions

Average Return

-38.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$5M
90.18%
5.47%
2.61%
1.74%
0.00% Others
A breakdown of Mark Foletta's holdings

Insider Roles

Dexcom
(DXCM)
Director
AMN Healthcare Services
(AMN)
Director
Regulus
(RGLS)
Director
Forte Biosciences
(FBRX)
EVP & CFO
+2 other positions
Roles that Mark Foletta holds in companies

Most Profitable Insider Trade

Stock:
Dexcom
(DXCM)
Rating:Informative Sell
Date:Sep 09, 2016 - Sep 09, 2017
Return:+23.30%
The most profitable trade made by Mark Foletta

Mark Foletta's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Biocept
Interim CFO
$0.00
Forte Biosciences
May 29, 2019
EVP & CFO
Uninformative Buy
21.45K
$85.38K
Enanta Pharmaceuticals
Director
Dexcom
Jun 20, 2024
Director
Uninformative Sell
702.00K
$4.41M
Regulus
Dec 06, 2017
Director
Uninformative Buy
64.00K
$127.78K
AMN Healthcare Services
Apr 23, 2024
Director
Uninformative Buy
95.73K
$267.53K
~AMBI
Ambit
List of latest transactions for each holding click on a transaction to see Mark Foletta's performance on stock

Mark Foletta insider profile FAQ

What is the percentage of profitable transactions made by Mark Foletta?
The percentage of profitable transactions made by Mark Foletta is 11%.
    What is the average return per transaction made by Mark Foletta?
    The average return per transaction made by Mark Foletta is -38.60%.
      What stocks does Mark Foletta hold?
      Mark Foletta holds: BIOCQ, FBRX, ENTA, DXCM, RGLS, AMN, ~AMBI stocks.
        What was Mark Foletta’s latest transaction?
        Mark Foletta latest transaction was an Uninformative Buy of ―.
          What was Mark Foletta's most profitable transaction?
          Mark Foletta’s most profitable transaction was an Informative Sell of DXCM stock on September 9, 2016. The return on the trade was 23.30%.
            What is Mark Foletta's role in Biocept?
            Mark Foletta's role in Biocept is Interim CFO.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.